查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1592909

流感疫苗市場：按疫苗類型、年齡層、給藥途徑、分銷管道分類 - 全球預測 2025-2030

Influenza Vaccine Market by Vaccine Type (Inactivated, Live Attenuated, Recombinant), Age Group (Adolescent Vaccination, Adult Vaccination, Infant Vaccination), Administration Route, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年流感疫苗市值為79.2億美元，預計2024年將達到86.1億美元，複合年成長率為9.01%，到2030年將達到144.9億美元。

流感疫苗市場包括預防流感病毒傳播的疫苗的開發、生產和分銷。該市場是由控制季節性流感爆發的需求所驅動的，季節性流感在全球範圍內構成了重大的健康挑戰。主要用途是政府衛生部門、醫療機構和私人診所開展的免疫計劃，最終用途是針對所有年齡段的個人，特別是老年人、幼兒和免疫力較弱的人等弱勢群體。 。影響成長的關鍵因素包括政府和私人對流感疫苗接種計劃的投資增加、疫苗技術的持續進步以及對季節性流感對健康影響的認知的提高。市場開拓機會包括新興市場的擴張、對提供廣泛保護的四價疫苗不斷成長的需求以及無針疫苗接種等創新的給藥方法。為了利用這一點，公司應該專注於開發更有效、提供更長時間保護的疫苗，並擴大教育宣傳活動以提高疫苗接種率。然而，市場成長面臨疫苗接種猶豫、研發成本高以及預測未來流感株以製定有效疫苗的複雜性等挑戰。它也受到監管障礙和非專利藥製造商競爭的限制。 mRNA 技術的使用、增強的疫苗儲存解決方案和改進的快速疫苗生產方法等領域的創新有可能帶來重大進展。畢竟，這個市場的特點是其動態性，流感病毒株的反覆突變以及對疫苗不斷更新的需求，為產品差異化和市場滲透提供了持續的機會。了解這些方面將有助於該行業的公司策略性地應對挑戰和機遇，推動永續業務成長。

主要市場統計
基準年[2023] 79.2億美元
預測年份 [2024] 86.1億美元
預測年份 [2030] 144.9億美元
複合年成長率（%） 9.01%

市場動態：揭示快速發展的流感疫苗市場的關鍵市場洞察

供需的動態交互作用正在改變流感疫苗市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 呼吸道疾病盛行率增加
    • 疫苗接種作為預防流感病毒感染的關鍵公共衛生措施
    • 季節性流感的臨床試驗和疫苗開發管道
    • 政府支持呼吸系統健康的舉措
  • 市場限制因素
    • 醫療基礎設施不足和意識有限
  • 市場機會
    • 主要企業研發費用增加
    • 透過分銷和開發合作增加疫苗的供應
    • 多種針對動物甲型流感病毒的候選疫苗正在開發中
  • 市場挑戰
    • 客戶對呼吸道疾病疫苗接種的信任與信心
    • 疫苗研究和開發面臨著不斷變化的菌株的挑戰。

波特五力：駕馭流感疫苗市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解流感疫苗市場的外部影響

外部宏觀環境因素對流感疫苗市場的表現動態起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解流感疫苗市場的競爭格局

流感疫苗市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣式流感疫苗市場供應商的績效評估

FPNV定位矩陣是評估流感疫苗市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製流感疫苗市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，對流感疫苗市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 呼吸道疾病盛行率增加
      • 疫苗接種作為預防流感病毒感染的關鍵公共衛生措施
      • 季節性流感臨床試驗和疫苗開發正在進行中
      • 政府支持呼吸系統健康的舉措
    • 抑制因素
      • 分銷基礎設施薄弱且意識有限
    • 機會
      • 主要市場參與者增加研發支出
      • 透過分銷和開發之間的合作提高疫苗的可用性
      • 多種針對動物甲型流感病毒的候選疫苗正在開發中
    • 任務
      • 客戶對呼吸道疾病疫苗的信任與信心
      • 株不斷變化，疫苗研發面臨挑戰
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 流感疫苗市場（依疫苗類型）

  • 惰性
  • 活病毒疫苗
  • 重組

第7章流感疫苗市場：依年齡層別

  • 青少年疫苗接種
  • 成人疫苗接種
  • 嬰兒疫苗接種

第8章依給藥途徑的流感疫苗市場

  • 肌肉注射
  • 鼻內
  • 口服

第9章流感疫苗市場：依通路分類

  • 政府醫療辦公室
  • 醫院/診所
  • 零售藥房
  • 急診室

第10章美洲流感疫苗市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太流感疫苗市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東和非洲流感疫苗市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • AstraZeneca PLC
  • Bayer AG
  • BioDiem
  • BiondVax Pharmaceuticals Ltd.
  • Bristol-Myers Squibb Company
  • CanSino Biologics Inc.
  • Daiichi Sankyo Company, Limited
  • Emergent BioSolutions Inc.
  • Eurocept Group
  • Fluart Innovative Vaccines Kft.
  • Gamma Vaccines Pty Ltd
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Seqirus GmbH
  • Serum Institute of India Pvt. Ltd.
  • Sinovac Biotech Ltd.
  • Swedish Orphan Biovitrum AB
Product Code: MRR-032A67D913E1

The Influenza Vaccine Market was valued at USD 7.92 billion in 2023, expected to reach USD 8.61 billion in 2024, and is projected to grow at a CAGR of 9.01%, to USD 14.49 billion by 2030.

The influenza vaccine market encompasses the development, production, and distribution of vaccines designed to prevent the spread of influenza viruses. This market is driven by the necessity to control seasonal flu outbreaks, which result in significant health challenges globally. The primary applications include immunization programs run by government health departments, healthcare facilities, and private clinics, while the end-use scope extends to individuals across all age groups, especially vulnerable populations such as the elderly, young children, and those with weakened immune systems. Key influencing growth factors include increased government and private investments in flu vaccination programs, continuous advancements in vaccine technology, and heightened awareness about seasonal influenza's health impacts. Opportunities within the market are notably led by emerging markets in developing nations, rising demand for quadrivalent vaccines offering broader protection, and innovative delivery methods such as needle-free vaccine administrations. To capitalize on these, businesses should focus on developing more effective vaccines with longer durations of protection and expanding educational campaigns to boost vaccination rates. However, market growth faces challenges like vaccine hesitancy, high research and development costs, and the complexity of predicting future influenza strains for effective vaccine formulation. Limitations also arise from regulatory hurdles and competition from generic manufacturers. Innovating in areas such as the use of mRNA technology, enhancing vaccine storage solutions, and improving rapid vaccine production methods could drive significant advancements. Ultimately, the market is characterized by its dynamic nature, necessitated by recurring influenza strain mutations and the constant requirement for updated vaccines, providing ongoing opportunities for product differentiation and market penetration. Understanding these facets, companies in the sector can strategically navigate the challenges and opportunities to drive sustainable business growth.

KEY MARKET STATISTICS
Base Year [2023] USD 7.92 billion
Estimated Year [2024] USD 8.61 billion
Forecast Year [2030] USD 14.49 billion
CAGR (%) 9.01%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Influenza Vaccine Market

The Influenza Vaccine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing Prevalence of Respiratory Disorders
    • Immunization as a Major Public Health Measures for the Prevention of Influenza Virus Infection
    • Clinical Trials and Vaccine Developments in Pipeline for Seasonal Influenzas
    • Government Initiatives Supporting Respiratory Health
  • Market Restraints
    • Lack of Inadequate Delivery Infrastructure & Limited Awareness
  • Market Opportunities
    • Increasing R&D Expenditure by Leading Market Players
    • Increasing Vaccine Availability through Distribution and Development Collaborations
    • Several Vaccine Candidates under Development against Animal Influenza A Virus
  • Market Challenges
    • Customers Trust and Confidence in Respiratory Disease Vaccination
    • Vaccine Research and Development are getting Challenged by the Constant Variations in Strains

Porter's Five Forces: A Strategic Tool for Navigating the Influenza Vaccine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Influenza Vaccine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Influenza Vaccine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Influenza Vaccine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Influenza Vaccine Market

A detailed market share analysis in the Influenza Vaccine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Influenza Vaccine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Influenza Vaccine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Influenza Vaccine Market

A strategic analysis of the Influenza Vaccine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Influenza Vaccine Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AstraZeneca PLC, Bayer AG, BioDiem, BiondVax Pharmaceuticals Ltd., Bristol-Myers Squibb Company, CanSino Biologics Inc., Daiichi Sankyo Company, Limited, Emergent BioSolutions Inc., Eurocept Group, Fluart Innovative Vaccines Kft., Gamma Vaccines Pty Ltd, GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., Sanofi S.A., Seqirus GmbH, Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., and Swedish Orphan Biovitrum AB.

Market Segmentation & Coverage

This research report categorizes the Influenza Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Vaccine Type, market is studied across Inactivated, Live Attenuated, and Recombinant.
  • Based on Age Group, market is studied across Adolescent Vaccination, Adult Vaccination, and Infant Vaccination.
  • Based on Administration Route, market is studied across Intramuscular, Intranasal, and Oral.
  • Based on Distribution Channel, market is studied across Government Medical Office, Hospital & Clinic, Retail Pharmacy, and Urgent Care Unit.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing Prevalence of Respiratory Disorders
      • 5.1.1.2. Immunization as a Major Public Health Measures for the Prevention of Influenza Virus Infection
      • 5.1.1.3. Clinical Trials and Vaccine Developments in Pipeline for Seasonal Influenzas
      • 5.1.1.4. Government Initiatives Supporting Respiratory Health
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of Inadequate Delivery Infrastructure & Limited Awareness
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing R&D Expenditure by Leading Market Players
      • 5.1.3.2. Increasing Vaccine Availability through Distribution and Development Collaborations
      • 5.1.3.3. Several Vaccine Candidates under Development against Animal Influenza A Virus
    • 5.1.4. Challenges
      • 5.1.4.1. Customers Trust and Confidence in Respiratory Disease Vaccination
      • 5.1.4.2. Vaccine Research and Development are getting Challenged by the Constant Variations in Strains
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Influenza Vaccine Market, by Vaccine Type

  • 6.1. Introduction
  • 6.2. Inactivated
  • 6.3. Live Attenuated
  • 6.4. Recombinant

7. Influenza Vaccine Market, by Age Group

  • 7.1. Introduction
  • 7.2. Adolescent Vaccination
  • 7.3. Adult Vaccination
  • 7.4. Infant Vaccination

8. Influenza Vaccine Market, by Administration Route

  • 8.1. Introduction
  • 8.2. Intramuscular
  • 8.3. Intranasal
  • 8.4. Oral

9. Influenza Vaccine Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Government Medical Office
  • 9.3. Hospital & Clinic
  • 9.4. Retail Pharmacy
  • 9.5. Urgent Care Unit

10. Americas Influenza Vaccine Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Influenza Vaccine Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Influenza Vaccine Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AstraZeneca PLC
  • 3. Bayer AG
  • 4. BioDiem
  • 5. BiondVax Pharmaceuticals Ltd.
  • 6. Bristol-Myers Squibb Company
  • 7. CanSino Biologics Inc.
  • 8. Daiichi Sankyo Company, Limited
  • 9. Emergent BioSolutions Inc.
  • 10. Eurocept Group
  • 11. Fluart Innovative Vaccines Kft.
  • 12. Gamma Vaccines Pty Ltd
  • 13. GlaxoSmithKline PLC
  • 14. Johnson & Johnson
  • 15. Merck & Co., Inc.
  • 16. Pfizer Inc.
  • 17. Sanofi S.A.
  • 18. Seqirus GmbH
  • 19. Serum Institute of India Pvt. Ltd.
  • 20. Sinovac Biotech Ltd.
  • 21. Swedish Orphan Biovitrum AB

LIST OF FIGURES

  • FIGURE 1. INFLUENZA VACCINE MARKET RESEARCH PROCESS
  • FIGURE 2. INFLUENZA VACCINE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. INFLUENZA VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. INFLUENZA VACCINE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. INFLUENZA VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. INFLUENZA VACCINE MARKET DYNAMICS
  • TABLE 7. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY ADOLESCENT VACCINATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY ADULT VACCINATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY INFANT VACCINATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY GOVERNMENT MEDICAL OFFICE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY HOSPITAL & CLINIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY URGENT CARE UNIT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 192. INFLUENZA VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 193. INFLUENZA VACCINE MARKET, FPNV POSITIONING MATRIX, 2023